Rockwell Medical Data Safety Monitoring Board Recommends SFP Phase III Efficacy Studies to Continue as Planned

Rockwell Medical Data Safety Monitoring Board Recommends SFP Phase III Efficacy Studies to Continue as Planned

[at noodls] – DSMB’s Fourth and Final Review Finds No Safety Indication to Alter or Stop SFP Iron Trials WIXOM, MI — (Marketwire) — 12/18/12 — Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical … more

View todays social media effects on RMTI

View the latest stocks trending across Twitter. Click to view dashboard

See who Rockwell is hiring next, click here to view

Share this post